Company: ABBV
Filing Date: 2025-02-14
Form Type: 10-K
Source: 0001551152-25-000020
Chunk: 258

Company: AbbVie Inc.
Filing Date: 2025-02-14
Form: 10-K
Item: Item 3
Chunk 258
---
 of December 31, 2022(1,513)464 (1,458)308 (2,199)Other comprehensive income (loss) before reclassifications407 (311)(23)(10)63 Net gains reclassified from accumulated other comprehensive loss— (88)(7)(74)(169)Net current-period other comprehensive income (loss)407 (399)(30)(84)(106)Balance as of December 31, 2023(1,106)65 (1,488)224 (2,305)Other comprehensive income (loss) before reclassifications(1,008)580 799 155 526 Net losses (gains) reclassified from accumulated other comprehensive loss— (96)25 (75)(146)Net current-period other comprehensive income (loss)(1,008)484 824 80 380 Balance as of December 31, 2024$(2,114)$549 $(664)$304 $(1,925)Other comprehensive income (loss) for 2024 included pension and post-employment benefit plan gains of $824 million primarily due to actuarial gains driven by higher discount rates. Other comprehensive income (loss) for 2024 also included foreign currency translation adjustments totaling losses of $1.0 billion principally due to the impact of the weakening of the Euro on the translation of the company's Euro-denominated assets and the offsetting impact of net investment hedging activities totaling gains of $484 million. Other comprehensive income (loss) for 2023 included foreign currency translation adjustments totaling gains of $407 million principally due to the impact of the strengthening of the Euro on the translation of the company’s Euro-denominated assets and the offsetting impact of net investment hedging activities totaling losses of $399 million. Other comprehensive income for 2022 included pension and post-employment benefit plan gains of $1.1 billion primarily due to actuarial gains driven by higher discount rates partially offset by losses on plan assets. Other comprehensive income (loss) for 2022 also included foreign currency translation adjustments totaling losses of $943 million principally due to the impact of the weakening of the Euro on the translation of the company's Euro-denominated assets and the offsetting impact of net investment hedging activities totaling gains of $555 million.

91     |  2024 Form 10-K

The table below presents the impact on AbbVie's consolidated statements of earnings for significant amounts